Share on StockTwits
 

Equities research analysts at Cowen and Company increased their price target on shares of Dyax Corp. (NASDAQ:DYAX) from $10.00 to $12.50 in a research note issued to investors on Wednesday, Analyst Ratings Network reports. Cowen and Company’s target price would suggest a potential upside of 23.27% from the company’s current price.

A number of other analysts have also recently weighed in on DYAX. Analysts at Leerink Swann raised their price target on shares of Dyax Corp. from $8.00 to $12.00 in a research note on Wednesday. They now have an “outperform” rating on the stock. Separately, analysts at Needham & Company raised their price target on shares of Dyax Corp. from $7.50 to $13.00 in a research note on Tuesday, February 18th. They now have a “buy” rating on the stock. Finally, analysts at Wedbush initiated coverage on shares of Dyax Corp. in a research note on Monday, January 13th. They set an “outperform” rating and a $11.00 price target on the stock. Three analysts have rated the stock with a buy rating, Dyax Corp. currently has a consensus rating of “Buy” and an average target price of $12.00.

Shares of Dyax Corp. (NASDAQ:DYAX) traded up 6.71% during mid-day trading on Wednesday, hitting $10.82. The stock had a trading volume of 2,967,619 shares. Dyax Corp. has a 52 week low of $2.26 and a 52 week high of $10.55. The stock has a 50-day moving average of $8.85 and a 200-day moving average of $7.23. The company’s market cap is $1.310 billion.

In other Dyax Corp. news, VP Andrew D. Ashe sold 2,723 shares of Dyax Corp. stock in a transaction that occurred on Wednesday, February 26th. The stock was sold at an average price of $10.10, for a total value of $27,502.30. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Dyax Corp. (NASDAQ:DYAX), is a biopharmaceutical company with two business elements: Angioedema Franchise and Phage Display Licensing and Funded Research Program.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.